Cinnarizin 25 mg – [56 tablets]

Selective slow calcium channel blocker, decreases influx of calcium ions into cells and decreases their content in plasma membrane depot, decreases tone of arteriolar smooth muscle, increases vasodilatory action of carbon dioxide. By directly affecting vascular smooth muscle, it reduces their response to biogenic substances (adrenaline, noradrenaline, dopamine, angiotensin, vasopressin). It has a vasodilator effect (especially on brain vessels), without a significant effect on blood pressure. It has moderate antihistamine activity, reduces the excitability of the vestibular apparatus, reduces the tone of the sympathetic nervous system. Effective both at initial and at chronic insufficiency of cerebral circulation (including patients in the residual stage of ischemic stroke). In patients with peripheral circulatory disorders improves blood supply to organs and tissues (including myocardium). Increases the elasticity of red blood cell membranes, their ability to deform, reduces blood viscosity. Increases muscle resistance to hypoxia.

Ischemic stroke, post-stroke conditions (including post-hemorrhagic stroke), conditions after craniocerebral injuries, discirculatory encephalopathy, vestibular disorders (including Meniere’s disease; vertigo, tinnitus, nystagmus, nausea and vomiting of labyrinthine origin), prevention of kinetosis (“road sickness” – sea and air sickness), migraine (prevention of attacks), senile dementia; Peripheral circulatory disorders (“intermittent” claudication, obliterating atherosclerosis, obliterating thrombangiitis (Buerger’s disease), Raynaud’s disease, diabetic angiopathy, thrombophlebitis, trophic disorders (including trophic and varicose veins), and other disorders of the peripheral nervous system. including trophic and varicose ulcers, pre-gangrenous conditions).

Contraindications .

Hypersensitivity, pregnancy, lactation.

With caution:

With caution in Parkinson’s disease.